###begin article-title 0
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 38 46 <span type="species:ncbi:9606">Patients</span>
Novel Mutations in TARDBP (TDP-43) in Patients with Familial Amyotrophic Lateral Sclerosis
###end article-title 0
###begin p 1
Current address: Neuroscience Drug Discovery, Merck Research Laboratories, Boston, Massachusetts, United States of America
###end p 1
###begin p 2
Conceived and designed the experiments: NJR MB MH LP RR. Performed the experiments: NJR YJZ MB JMG NAF YFX RJC LP RR. Analyzed the data: NJR IRM LP RR. Contributed reagents/materials/analysis tools: HS BJK KK JS CV ES CL EHB DHG DSK HM RCP NRC CES KBB BB NRGR ZKW RJC DWD LP RR. Wrote the paper: NJR YJZ RJC KBB NRGR ZKW DWD IRM LP RR.
###end p 2
###begin p 3
###xml 346 352 346 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 581 587 581 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 819 825 819 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 1547 1553 1535 1541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 1715 1721 1703 1709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 406 414 <span type="species:ncbi:9606">patients</span>
###xml 669 677 <span type="species:ncbi:9606">patients</span>
###xml 909 917 <span type="species:ncbi:9606">patients</span>
###xml 965 973 <span type="species:ncbi:9606">patients</span>
###xml 999 1007 <span type="species:ncbi:9606">patients</span>
###xml 1170 1178 <span type="species:ncbi:9606">patients</span>
###xml 1369 1376 <span type="species:ncbi:9606">patient</span>
The TAR DNA-binding protein 43 (TDP-43) has been identified as the major disease protein in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin inclusions (FTLD-U), defining a novel class of neurodegenerative conditions: the TDP-43 proteinopathies. The first pathogenic mutations in the gene encoding TDP-43 (TARDBP) were recently reported in familial and sporadic ALS patients, supporting a direct role for TDP-43 in neurodegeneration. In this study, we report the identification and functional analyses of two novel and one known mutation in TARDBP that we identified as a result of extensive mutation analyses in a cohort of 296 patients with variable neurodegenerative diseases associated with TDP-43 histopathology. Three different heterozygous missense mutations in exon 6 of TARDBP (p.M337V, p.N345K, and p.I383V) were identified in the analysis of 92 familial ALS patients (3.3%), while no mutations were detected in 24 patients with sporadic ALS or 180 patients with other TDP-43-positive neurodegenerative diseases. The presence of p.M337V, p.N345K, and p.I383V was excluded in 825 controls and 652 additional sporadic ALS patients. All three mutations affect highly conserved amino acid residues in the C-terminal part of TDP-43 known to be involved in protein-protein interactions. Biochemical analysis of TDP-43 in ALS patient cell lines revealed a substantial increase in caspase cleaved fragments, including the approximately25 kDa fragment, compared to control cell lines. Our findings support TARDBP mutations as a cause of ALS. Based on the specific C-terminal location of the mutations and the accumulation of a smaller C-terminal fragment, we speculate that TARDBP mutations may cause a toxic gain of function through novel protein interactions or intracellular accumulation of TDP-43 fragments leading to apoptosis.
###end p 3
###begin title 4
Author Summary
###end title 4
###begin p 5
###xml 446 454 <span type="species:ncbi:9606">patients</span>
###xml 622 630 <span type="species:ncbi:9606">patients</span>
###xml 742 750 <span type="species:ncbi:9606">patients</span>
###xml 855 863 <span type="species:ncbi:9606">patients</span>
###xml 903 911 <span type="species:ncbi:9606">patients</span>
The abnormal accumulation of disease proteins in neuronal cells of the brain is a characteristic feature of many neurodegenerative diseases. Rare mutations in the genes that encode the accumulating proteins have been identified in these disorders and are crucial for the development of cell and animal models used to study neurodegeneration. Recently, the TAR DNA-binding protein 43 (TDP-43) was identified as the disease accumulating protein in patients with frontotemporal lobar degeneration with ubiquitin inclusions (FTLD-U) and in amyotrophic lateral sclerosis (ALS). TDP-43 was also found in the brains of 20-30% of patients with Alzheimer's disease (AD). Here, we evaluated whether mutations in TDP-43 cause disease in a cohort of 296 patients presenting with FTLD, ALS or AD. We identified three missense mutations in three out of 92 familial ALS patients (3.3%), and no mutations in AD or FTLD patients. All the identified mutations clustered in exon 6, which codes for a highly conserved region in the C-terminal part of the TDP-43 protein, which is known to be involved in the interaction of TDP-43 with other proteins. We conclude that mutations in TDP-43 are a rare cause of familial ALS, but so far are not found in other neurodegenerative diseases.
###end p 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 143 149 143 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 417 439 417 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TDP-43 proteinopathies</italic>
###xml 439 442 439 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Arai1">[1]</xref>
###xml 443 446 443 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Wider1">[5]</xref>
###xml 865 868 865 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Neumann1">[4]</xref>
###xml 869 872 869 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Winton1">[6]</xref>
###xml 873 876 873 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Zhang1">[7]</xref>
###xml 1139 1142 1139 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-AmadorOrtiz1">[8]</xref>
###xml 1143 1147 1143 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Probst1">[12]</xref>
###xml 1307 1311 1307 1311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Buratti1">[13]</xref>
###xml 951 959 <span type="species:ncbi:9606">patients</span>
###xml 998 1006 <span type="species:ncbi:9606">patients</span>
###xml 1050 1058 <span type="species:ncbi:9606">patients</span>
###xml 1098 1106 <span type="species:ncbi:9606">patients</span>
Transactive response DNA binding protein with a molecular weight of 43 kDa (TDP-43) is a ubiquitously expressed nuclear protein encoded by the TARDBP gene, located on chromosome 1p36. TDP-43 was identified as the major disease accumulated protein in ubiquitinated neuronal cytoplasmic (NCI) and neuronal intranuclear inclusions (NII), that define a growing class of neurological diseases, collectively referred to as TDP-43 proteinopathies[1]-[5]. These diseases include amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD) with ubiquitin immunoreactive, tau negative inclusions (FTLD-U) and FTLD with motor neuron disease (FTLD-MND). In TDP-43 proteinopathies, TDP-43 is relocated from the nucleus to the cytoplasm and sequestered into inclusions that are mainly composed of hyperphosphorylated and C-terminally truncated TDP-43 fragments [4],[6],[7]. TDP-43 immunoreactive histopathology has also been reported in 20-30% of patients with Alzheimer's disease (AD), 70% of patients with hippocampal sclerosis (HpScl), 33% of patients with Pick's disease and in a subset of patients with Lewy-body related diseases [8]-[12]. TDP-43 is a highly conserved protein, containing 2 RNA recognition motifs and a C-terminal glycine-rich domain, known to promote protein-protein interactions [13].
###end p 7
###begin p 8
###xml 59 60 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sub>
###xml 131 135 131 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Buratti1">[13]</xref>
###xml 394 398 394 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Buratti2">[14]</xref>
###xml 399 403 399 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Mercado1">[15]</xref>
###xml 460 464 460 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Gregory1">[16]</xref>
TDP-43 can bind to the common microsatellite region (GU/GT)n in RNA and DNA, with proposed functions in transcriptional regulation [13]. Most recent research has focused on the role of TDP-43 in the regulation of exon 9 alternative splicing in the cystic fibrosis transmembrane conductance regulator gene, however, additional targets have been identified and others likely await identification [14],[15]. TDP-43 has also been implicated in microRNA biogenesis [16].
###end p 8
###begin p 9
###xml 282 286 282 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Piemonte1">[17]</xref>
###xml 287 291 287 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Rademakers1">[19]</xref>
###xml 343 347 343 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD1</italic>
###xml 436 440 424 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Rosen1">[20]</xref>
###xml 489 493 477 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD1</italic>
###xml 571 575 559 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Mackenzie1">[21]</xref>
###xml 639 643 627 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Rademakers1">[19]</xref>
###xml 733 737 721 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGRN</italic>
###xml 782 786 770 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Baker1">[22]</xref>
###xml 787 791 775 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Cruts1">[23]</xref>
###xml 836 840 824 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Gass1">[24]</xref>
###xml 945 948 933 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VCP</italic>
###xml 1016 1022 1004 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1129 1133 1117 1121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Morita1">[25]</xref>
###xml 1134 1138 1122 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Watts1">[29]</xref>
###xml 180 188 <span type="species:ncbi:9606">patients</span>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
###xml 427 435 <span type="species:ncbi:9606">patients</span>
###xml 562 570 <span type="species:ncbi:9606">patients</span>
###xml 817 825 <span type="species:ncbi:9606">patients</span>
ALS and FTLD-U are etiologically complex disorders with genetic as well as environmental factors contributing to the disease. A positive family history is reported in 5-10% of ALS patients and in up to 50% of FTLD-U patients, often with an autosomal dominant pattern of inheritance [17]-[19]. Mutations in the Cu/Zn superoxide dismutase gene (SOD1) account for approximately10-20% of familial and 1-2% of apparent sporadic ALS patients [20]. However, TDP-43 inclusions were not present in SOD1 mutation carriers, suggesting a distinct disease mechanism in these patients [21]. The genetic basis of FTLD-U is just starting to be understood [19]. Loss-of-function mutations in the gene encoding the secreted growth factor progranulin (PGRN) are a major known cause of familial FTLD-U [22],[23], explaining up to 25% of patients worldwide [24]. Other rare genetic causes of familial FTLD-U include mutations in the valosin containing protein gene (VCP) and the gene encoding the charged multivesicular body protein 2B (CHMP2B), while some families with a combination of FTLD and ALS show genetic linkage to a locus on chromosome 9p [25]-[29].
###end p 9
###begin p 10
###xml 214 220 214 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 323 329 323 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 484 488 484 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Gitcho1">[30]</xref>
###xml 489 493 489 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Sreedharan1">[31]</xref>
###xml 713 717 701 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Kabashi1">[32]</xref>
###xml 774 780 762 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 982 988 970 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 1159 1165 1147 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 411 419 <span type="species:ncbi:9606">patients</span>
###xml 609 617 <span type="species:ncbi:9606">patients</span>
###xml 840 848 <span type="species:ncbi:9606">patients</span>
Since rare missense mutations and multiplications have been identified in genes encoding the major constituents of the pathological deposits in several neurodegenerative diseases, we hypothesized that mutations in TARDBP may contribute to the development of TDP-43 proteinopathies. In fact, the first missense mutations in TARDBP were recently discovered in 2 autosomal dominant ALS families and 2 sporadic ALS patients, supporting the central role for TDP-43 in disease pathogenesis [30],[31]. A large population-based study further identified 8 different missense mutations in 3 familial and 6 sporadic ALS patients and showed accumulation of a detergent-insoluble TDP-43 protein product of approximately28 kDa [32]. Here, we report on the extensive mutation screening of TARDBP in a diverse cohort of clinical and pathological confirmed patients with neurodegenerative diseases characterized by TDP-43 pathology, which led to the identification of 3 additional ALS families with TARDBP mutations. We further show accumulation of proteolytic cleaved fragments with a molecular weight of approximately 35 and 25 kDa in lymphoblastoid cell lines derived from TARDBP mutation carriers.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
TARDBP Mutation Analyses
###end title 12
###begin p 13
###xml 13 22 13 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in silico</italic>
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 314 320 314 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 442 448 442 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 763 770 763 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000193-t001">Table 1</xref>
###xml 772 780 772 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000193-g001">Figure 1</xref>
###xml 884 890 884 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 1166 1174 1166 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000193.s001">Table S1</xref>
###xml 1185 1191 1185 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 77 82 <span type="species:ncbi:9606">human</span>
###xml 487 495 <span type="species:ncbi:9606">patients</span>
###xml 504 512 <span type="species:ncbi:9606">patients</span>
###xml 632 640 <span type="species:ncbi:9606">patients</span>
###xml 689 697 <span type="species:ncbi:9606">patients</span>
###xml 822 830 <span type="species:ncbi:9606">patients</span>
###xml 956 964 <span type="species:ncbi:9606">patients</span>
###xml 971 979 <span type="species:ncbi:9606">patients</span>
###xml 1220 1228 <span type="species:ncbi:9606">patients</span>
###xml 1251 1259 <span type="species:ncbi:9606">patients</span>
We performed in silico analyses of the TARDBP gene structure by alignment of human spliced expressed sequence tags listed in the UCSC genome browser (). This led to the identification of a novel 5' non-coding exon (exon 0) in addition to the known non-coding exon 1 and the 5 coding exons that are included in the TARDBP reference mRNA sequence (NCBI accession number NM_007375). Sequencing analyses of the 5 coding and 2 non-coding exons of TARDBP in our initial cohort of 176 clinical patients and 120 patients with pathologically confirmed TDP-43 pathology revealed 3 heterozygous missense mutations in 3 of the 116 analyzed ALS patients (2.6%), while no mutations were detected in 180 patients affected with FTLD-U, FTLD-MND, AD, HpScl and Lewy-body disease (Table 1, Figure 1). Since all mutation carriers were index patients of autosomal dominant ALS families, the frequency of TARDBP mutations increased to 3.3% in the subpopulation of familial ALS patients (3/92 patients). One silent mutation (p.Ala66) and 18 additional sequence variants in intronic and non-coding regions were further identified, none of which was predicted to affect the TDP-43 protein (Table S1). Genomic TARDBP copy-number analyses in 208 patients including all 116 ALS patients did not reveal deletions or multiplications.
###end p 13
###begin title 14
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Missense mutations identified in TARDBP in familial ALS patients.
###end title 14
###begin p 15
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 452 458 452 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 742 748 742 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
###xml 267 272 <span type="species:ncbi:9606">Human</span>
(A) Pedigrees showing family history of ALS for three probands carrying TARDBP mutations. Black symbols represent patients affected with ALS; white symbols represent unaffected individuals. Pedigrees are constructed based on family history data provided by the NINDS Human Genetics Resource Center DNA and Cell Line Repository (). The alive/dead status of individuals is unknown. Arrowheads indicate the probands. The onset age of ALS symptoms and the TARDBP mutation identified are included below each proband. (B) DNA sequence traces observed in a sample from the proband of each family. The observed single base substitution and predicted amino acid change are indicated below each chromatogram. cDNA numbering is according to the largest TARDBP transcript (NM_007375.3) and starting at the translation initiation codon. Protein numbering is relative to the largest TDP-43 isoform (NP_031401.1).
###end p 15
###begin title 16
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients included in the TARDBP sequencing analyses.
###end title 16
###begin p 17
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 69 77 69 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000193-g002">Figure 2</xref>
###xml 691 697 691 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 93 100 <span type="species:ncbi:9606">patient</span>
###xml 353 360 <span type="species:ncbi:9606">patient</span>
###xml 517 524 <span type="species:ncbi:9606">patient</span>
###xml 960 968 <span type="species:ncbi:9606">patients</span>
###xml 1153 1158 <span type="species:ncbi:9606">Human</span>
All TARDBP mutations identified in this study are located in exon 6 (Figure 2). In the index patient of family A (ND10588), we identified the known c.1009 A>G mutation, predicted to substitute valine for methionine at codon 337 (p.M337V), and previously reported to segregate with disease in a large British autosomal dominant ALS kindred. In the index patient of family B (ND08308), a novel mutation c.1035 C>A was identified, predicted to change asparagine to a lysine at codon 345 (p.N345K). Finally, in the index patient of family C (ND08470), a novel mutation c.1147 A>G which predicts an isoleucine for a valine substitution at codon 383 (p.I383V) was identified. Sequence analysis of TARDBP exon 6 in 185 healthy control individuals did not identify these or other sequence variants. Using custom made TaqMan genotyping assays, the presence of p.M337V, p.N345K and p.I383V was further excluded in 640 US control individuals. Genotyping 652 sporadic ALS patients for these mutations did not identify additional mutation carriers. Since all 3 mutation carriers were obtained from the National Institute of Neurological Disorders and Stroke (NINDS) Human Genetics Resource Center DNA and Cell Line Repository (Coriell), DNA samples of relatives were unavailable for genetic studies and segregation of the mutations with disease could therefore not be determined.
###end p 17
###begin title 18
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
Overview of mutations identified to date in TARDBP.
###end title 18
###begin p 19
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 594 600 594 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 502 510 <span type="species:ncbi:9606">patients</span>
Schematic overview of the 7 TARDBP exons showing coding regions in dark blue and non-coding regions in light blue (top). The TDP-43 protein structure with location of the conserved domains is shown with protein numbering according to the largest isoforms NP_031401.1 (middle). Protein sequence alignment shows strong conservation in the C-terminal region of TDP-43 (bottom). Colored boxes indicate the position of known and novel TDP-43 mutations identified in sporadic (orange) and familial (red) ALS patients. TDP-43 mutations identified in this study are underlined. Orange and red lines in TARDBP gene and TDP-43 protein indicate approximate positions of the mutations. RRM = RNA recognition motif.
###end p 19
###begin title 20
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
Clinical Characteristics of TARDBP Mutation Carriers
###end title 20
###begin p 21
###xml 6 12 6 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 380 386 380 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 420 428 420 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000193.s002">Table S2</xref>
###xml 573 581 573 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000193-g001">Figure 1</xref>
###xml 861 867 861 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 63 70 <span type="species:ncbi:9606">patient</span>
###xml 220 228 <span type="species:ncbi:9606">patients</span>
###xml 430 438 <span type="species:ncbi:9606">Patients</span>
###xml 523 530 <span type="species:ncbi:9606">patient</span>
###xml 618 626 <span type="species:ncbi:9606">patients</span>
All 3 TARDBP mutation carriers were identified in the clinical patient series and were diagnosed by El Escorial criteria with probable or probable-lab supported ALS. Electromyography (EMG) examination was performed in 2 patients (ND10588 and ND08470) and was supportive of the diagnosis of ALS. A detailed overview of the distribution of upper and lower motor neuron signs in the TARDBP mutation carriers is included in Table S2. Patients ND10588 and ND08308 showed early onset ages of 38 and 39 years, respectively, while patient ND08470 showed symptom onset at 59 years (Figure 1). The initial presenting symptom in patients ND10588 and ND08470 was upper-limb ALS, while ND08308 suffered from lower-limb onset ALS. No signs of dementia or other atypical features of ALS were reported in any of the mutation carriers or their affected relatives. No autopsy of TARDBP mutation carriers was available.
###end p 21
###begin title 22
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
Allele Sharing Analyses of TARDBP p.M337V
###end title 22
###begin p 23
###xml 257 263 257 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 302 308 302 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 310 317 310 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000193-t002">Table 2</xref>
###xml 586 592 586 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
To investigate whether our US p.M337V mutation carrier and the previously reported p.M337V family from the UK are descendants of a common founder, we did an allele sharing study with 12 short tandem repeat (STR) markers spanning a region of 6.7 Mb flanking TARDBP, including 5 markers within 1.0 Mb of TARDBP (Table 2). We determined the disease haplotype in the UK family and compared this to the genotypes observed in ND10588 to detect allele sharing. Shared alleles were observed for 6 out of 12 STR markers in the region, however, only one marker (Chr1(AC)_11.06) directly flanking TARDBP was shared and the 264 bp allele identified at this marker was common in the population (62.4%). In addition, potentially shared alleles at all other markers in the region were also common (>28%). These results make it unlikely that p.M337V originated from a common founder.
###end p 23
###begin title 24
Allele sharing in p.M337V families.
###end title 24
###begin p 25
###xml 60 65 <span type="species:ncbi:9606">Human</span>
Genomic position relative to the UCSC genome browser on the Human Mar. 2006 Assembly ().
###end p 25
###begin p 26
###xml 50 57 <span type="species:ncbi:9606">patient</span>
Alleles that are shared between the UK family and patient ND10588 are in bold.
###end p 26
###begin title 27
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 57 65 <span type="species:ncbi:9606">Patients</span>
Biochemical Analysis of TARDBP Mutations in Familial ALS Patients
###end title 27
###begin p 28
###xml 129 135 117 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 349 353 337 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Kabashi1">[32]</xref>
###xml 439 445 427 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 783 789 771 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 965 973 953 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000193-g003">Figure 3</xref>
###xml 1044 1052 1032 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000193-g003">Figure 3</xref>
###xml 272 280 <span type="species:ncbi:9606">patients</span>
###xml 425 433 <span type="species:ncbi:9606">patients</span>
###xml 769 777 <span type="species:ncbi:9606">patients</span>
Kabashi and colleagues previously reported a substantial increase in a approximately28 kDa fragment in lymphoblastoid cells with TARDBP mutations in the presence of the proteasomal inhibitor, MG-132, but not in lymphoblastoid cells derived from control individuals or ALS patients suggesting an increase aggregation property of these TDP-43 mutants [32]. Based on this result, we performed a similar study and analyzed the 3 patients with TARDBP mutations identified in our study, 2 sporadic ALS cases and 5 control individuals in the presence or absence of MG-132. Consistent with the previous report, a marked increase in the accumulation of detergent insoluble TDP-43 protein fragments were observed in the lymphoblastoid cell lines treated with MG-132 derived from patients with TARDBP mutations but not those derived from control individuals. In our study, we sized the higher and lower TDP-43 C-terminal fragments at approximately 35 and 25 kDa respectively (Figure 3). A similar increase was also found in individuals with sporadic ALS (Figure 3).
###end p 28
###begin title 29
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
Biochemical analysis of TDP-43 in lymphoblastoid cell lines of TARDBP mutation carriers.
###end title 29
###begin p 30
###xml 128 134 128 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 210 216 210 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 318 324 318 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 100 108 <span type="species:ncbi:9606">patients</span>
###xml 183 191 <span type="species:ncbi:9606">patients</span>
###xml 360 368 <span type="species:ncbi:9606">patients</span>
Western blot analyses of protein lysates derived from lymphoblastoid cell lines from 3 familial ALS patients carrying different TARDBP mutations (p.M337V, p.N345K and p.I383V), 2 ALS patients (1 and 2) without TARDBP mutations and 5 healthy control individuals (Control 1-5). In lymphoblastoid cell lines derived from TARDBP mutation carriers and sporadic ALS patients an accumulation of 2 smaller C-terminal fragments of TDP-43 protein of approximately 35 and 25 kDa was observed in detergent-insoluble fractions treated with the proteasome inhibitor, MG-132. In lymphoblastoid cell lines derived from control individuals the levels of the 35 kDa fragment were substantially lower, and the 25 kDa fragment was mostly undetectable. Membranes from the soluble fraction were reprobed for beta-actin to monitor protein loading.
###end p 30
###begin p 31
###xml 551 559 523 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000193-g004">Figure 4</xref>
###xml 657 663 629 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 683 691 655 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000193-g003">Figure 3</xref>
###xml 1097 1105 1069 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000193-g004">Figure 4</xref>
###xml 1338 1346 1310 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000193-g004">Figure 4</xref>
We previously demonstrated that the proteolytic cleavage of TDP-43 by caspases can generate insoluble C-terminal fragments (35 and 25 kDa) similar to those found in diseased brains. Therefore, we investigated whether proteasome-induced toxicity was associated with proteolytic processing of endogenous TDP-43 in cell culture models. H4 neuroglioma cells were treated with either vehicle (DMSO) or proteasome inhibitor I (PSI) (10 microM) for 24 hours. In the presence of PSI, TDP-43 was cleaved into approximately35 and approximately25 kDa fragments (Figure 4), similar to the 35 and 25 kDa fragments found in the lymphoblastoid cell lines derived from the TARDBP mutation carriers (Figure 3). Similar results were obtained using MG-132 (data not shown). The inhibitory activity and toxicity of PSI also led to a marked increase in cleaved (active) capase-3 levels, which promotes apoptotic cell death and accumulates upon such inhibition. Furthermore, when we co-treated the cells with PSI and the caspase inhibitor, Z-VAD (OMe)-FMK, the generation of proteolytic TDP-43 fragments was inhibited (Figure 4). HSP70 immunoblot analysis was used to verify the inhibition of the proteasomal machinery. As expected, HSP70 levels were increased after PSI treatment and the levels persisted in the presence of caspase inhibitor Z-VAD (OMe)-FMK (Figure 4). Taken together, these data strongly suggest that proteasome inhibition is sufficient to promote proteolytic cleavage and accumulation of TDP-43 through a mechanism that implicates programmed cell death.
###end p 31
###begin title 32
Proteasome inhibition increases the proteolytic cleavage of TDP-43.
###end title 32
###begin p 33
Western blot analyses of H4 neuroglioma cells treated with the proteasome inhibitor, PSI (10 microM, 24 hours) and a pan-caspase inhibitor, Z-VAD-FMK (100 microM, 24 hours) separately or in combination. Treatment with PSI revealed an increase in proteolytic cleavage of TDP-43 fragments (35 and 25 kDa) and an increase in caspase-3 activity. Treatment with a pan-caspase inhibitor suppressed PSI-induced TDP-43 cleavage and caspase-3 activity. HSP70 levels were increased after PSI treatment and the levels persisted in the presence of a pan-caspase inhibitor. Similar results were obtained in 3 independent experiments.
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 264 267 264 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APP</italic>
###xml 276 280 276 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAPT</italic>
###xml 307 311 307 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SNCA</italic>
###xml 313 317 313 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Goate1">[33]</xref>
###xml 318 322 318 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Hutton1">[34]</xref>
###xml 373 379 373 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 547 553 547 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 828 834 828 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 959 963 959 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Gitcho1">[30]</xref>
###xml 964 968 964 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Kabashi1">[32]</xref>
###xml 969 973 969 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-VanDeerlin1">[35]</xref>
###xml 419 427 <span type="species:ncbi:9606">patients</span>
###xml 618 626 <span type="species:ncbi:9606">Patients</span>
###xml 683 691 <span type="species:ncbi:9606">patients</span>
###xml 950 958 <span type="species:ncbi:9606">patients</span>
The identification of rare mutations in genes encoding the major protein component of the pathologic brain depositions observed in familial neurodegenerative diseases has played a critical role in our current understanding of the molecular pathways underlying AD (APP), FTLD (MAPT) and Parkinson's disease (SNCA) [33],[34]. In this study, we performed mutation analyses of TARDBP, encoding TDP-43, in a large cohort of patients with neurodegenerative diseases characterized by TDP-43 pathology to determine if rare mutations or multiplications in TARDBP are involved in the genetic etiology of TDP-43 proteinopathies. Patients with a clinical diagnosis of ALS, FTLD or FTLD-ALS, and patients with pathologically confirmed TDP-43-proteinopathy were included in the analyses. In support of our hypothesis, 14 different pathogenic TARDBP missense mutations were reported by other researchers during the course of this study in familial and sporadic ALS patients [30]-[32],[35].
###end p 35
###begin p 36
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 386 392 386 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 505 509 505 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Kabashi1">[32]</xref>
###xml 638 642 638 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Sreedharan1">[31]</xref>
###xml 823 829 823 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 1104 1110 1104 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 1252 1258 1252 1258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 1279 1283 1279 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Gitcho1">[30]</xref>
###xml 1285 1289 1285 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Gijselinck1">[36]</xref>
###xml 1290 1294 1290 1294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Schumacher1">[38]</xref>
###xml 1323 1329 1323 1329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 1395 1401 1395 1401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 129 137 <span type="species:ncbi:9606">patients</span>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
###xml 372 380 <span type="species:ncbi:9606">patients</span>
###xml 516 524 <span type="species:ncbi:9606">patients</span>
###xml 621 629 <span type="species:ncbi:9606">patients</span>
###xml 724 732 <span type="species:ncbi:9606">patients</span>
###xml 744 752 <span type="species:ncbi:9606">patients</span>
###xml 805 813 <span type="species:ncbi:9606">patients</span>
###xml 895 903 <span type="species:ncbi:9606">patients</span>
###xml 928 933 <span type="species:ncbi:9606">Human</span>
###xml 1124 1132 <span type="species:ncbi:9606">patients</span>
###xml 1385 1393 <span type="species:ncbi:9606">patients</span>
We identified 2 novel TARDBP missense mutations (p.N345K and p.I383V) and the known p.M337V mutation in 3 out of 92 familial ALS patients (3.3%), while no mutations were identified in 24 sporadic ALS patients or 180 patients with other neurodegenerative diseases. p.M337V, p.N345K and p.I383V were excluded in 825 US control individuals and in 652 additional sporadic ALS patients. The TARDBP mutation frequency in our familial ALS cohort is comparable to the frequency reported by Kabashi and colleagues [32] (3/80 patients = 3.8%) but considerably higher than the frequency reported by Sreedharan and colleagues (1/154 patients = 0.6%) [31]. This may reflect the difference in study design, as a significant number of our patients were index patients of autosomal dominant ALS families, including all 3 patients carrying TARDBP mutations. Unfortunately, since all mutation carriers were index patients obtained from the NINDS Human Genetics Resource Center DNA and Cell Line Repository, DNA of affected relatives was not available to determine segregation of the mutations with disease. The absence of TARDBP mutations in patients with neurodegenerative diseases other than ALS in our study, confirms the lack of mutations and genetic association of TARDBP in FTLD populations [30], [36]-[38]. However, without extensive TARDBP sequence analyses in additional cohorts of FTLD and AD patients, TARDBP mutations cannot be excluded as a rare cause of these disorders.
###end p 36
###begin p 37
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 201 207 201 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
All TARDBP mutation carriers identified in this study presented with probable ALS according to El Escorial criteria in the absence of atypical clinical signs, in agreement with the previous reports on TARDBP mutation carriers.
###end p 37
###begin p 38
###xml 119 123 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Sreedharan1">[31]</xref>
###xml 531 537 531 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 702 706 702 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-AlChalabi1">[39]</xref>
###xml 707 711 707 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Parton1">[40]</xref>
###xml 1099 1105 1099 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 1153 1159 1153 1159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 159 166 <span type="species:ncbi:9606">patient</span>
###xml 601 608 <span type="species:ncbi:9606">patient</span>
###xml 799 806 <span type="species:ncbi:9606">patient</span>
###xml 1163 1171 <span type="species:ncbi:9606">patients</span>
The p.M337V mutation has previously been reported to segregate with disease in a British autosomal dominant ALS family [31]. We identified p.M337V in an index patient from a US family with a strong family history of ALS. Our mutation carrier showed upper limb-onset ALS at 38 years of age, 6 years younger than the earliest onset age reported in the British p.M337V family. Signs of dementia were not reported in any of the family members, consistent with the previous report. An allele sharing study using 12 STR markers flanking TARDBP did not support a common ancestor for the UK family and our US patient, although our set of analyzed markers would not have detected a very distant common ancestor [39],[40]. In addition, we cannot exclude the rare possibility that marker Chr1_11.28 mutated in patient ND10588 or that the genomic position of this marker is incorrect, which would leave open the possibility of a shared region of maximum 1.3 Mb (D1S1635-D1S434). In anyway, the identification of p.M337V in two genealogically unrelated ALS families adds further strength to the pathogenicity of TARDBP mutations and justifies mutation screening for TARDBP in patients with familial ALS.
###end p 38
###begin p 39
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 246 254 246 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000193-g002">Figure 2</xref>
###xml 859 865 857 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 1003 1009 1001 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 1009 1013 1007 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Gitcho1">[30]</xref>
###xml 432 439 <span type="species:ncbi:9606">patient</span>
###xml 1295 1303 <span type="species:ncbi:9606">patients</span>
Similar to 13 of the 14 previously reported TARDBP mutations, both novel missense mutations identified in this study were located in exon 6 encoding the highly conserved C-terminus of TDP-43, known to be involved in protein-protein interactions (Figure 2). p.N345K was identified in a 43 year old male with a 4 year history of ALS and an autosomal dominant family history. The p.I383V mutation was also identified in a familial ALS patient; however the onset age was 59 years, 2 decades later than the other 2 mutations identified in this study. This may reflect the more conservative amino acid substitution (Iso-->Val) or its more C-terminal location in the TDP-43 protein compared to the other mutations, which may induce a different disease mechanism. Alternatively, additional genetic and/or environmental factors may determine the disease expression of TARDBP mutations, as suggested by the wide onset age range (48-83 years) observed in the recently published family with the p.A315T mutation in TARDBP[30]. Finally, although there is strong evidence supporting that p.N345K and p.I383V are pathogenic, there remains the possibility that these mutations in fact represent rare benign polymorphisms. Definitive confirmation of their pathogenic nature will depend on finding additional ALS patients carrying these mutations.
###end p 39
###begin p 40
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 192 198 192 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 266 272 266 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 310 318 310 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000193-g003">Figure 3</xref>
###xml 494 497 494 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Zhang1">[7]</xref>
###xml 523 529 523 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 820 826 820 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 1044 1048 1044 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000193-Kabashi1">[32]</xref>
###xml 1345 1353 1345 1353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000193-g004">Figure 4</xref>
###xml 132 137 <span type="species:ncbi:9606">human</span>
###xml 249 257 <span type="species:ncbi:9606">patients</span>
###xml 321 328 <span type="species:ncbi:9606">Patient</span>
###xml 1335 1343 <span type="species:ncbi:9606">patients</span>
To determine the pathological significance of TARDBP missense mutations on the post-translational processing of TDP-43, we examined human lymphoblastoid cell lines derived from all 3 familial TARDBP mutation carriers identified in this study, 2 ALS patients without TARDBP mutations and 5 control individuals (Figure 3). Patient cell lines revealed a substantial increase in a proteolytic cleaved fragment with a molecular weight of approximately 35 and 25 kDa consistent with caspase cleavage [7]. These data suggest that TARDBP mutations may cause a toxic gain of function through novel protein interactions or intracellular accumulation, particularly of caspase fragments. Kabashi and colleagues previously reported a similar substantial increase in a fragment of approximately 28 kDa in lymphoblastoid cell lines of TARDBP mutation carriers. This fragment accumulated in the presence of a proteasome inhibitor (MG-132), which led the authors to speculate that this TDP-43 product is likely degraded by the ubiquitin-proteasome system (UPS) [32]. While we can't exclude the enhanced aggregation of their mutants in the presence of the inhibitor, our data suggests that proteasome-induced toxicity enhances proteolytic cleavage of TDP-43 into 35 and 25 kDa fragments, resulting in cleavage fragments similar to those observed in ALS patients (Figure 4). Although we can't exclude the possibility that these fragments may be degraded by the UPS, it is likely that the accumulation of these fragments is primarily mediated by caspase cleavage.
###end p 40
###begin p 41
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 164 170 164 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 288 294 288 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
In conclusion, our findings support that TARDBP mutations are a rare cause of ALS, but so far are not found in other neurodegenerative diseases. Since all reported TARDBP mutations cluster in exon 6 encoding a highly conserved region of the TDP-43 protein, selective mutation analyses of TARDBP exon 6 in familial and sporadic ALS may be warranted.
###end p 41
###begin title 42
Materials and Methods
###end title 42
###begin title 43
Study Populations
###end title 43
###begin p 44
###xml 709 716 705 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000193-t001">Table 1</xref>
###xml 1923 1929 1919 1925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 1964 1972 1960 1968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000193.s003">Table S3</xref>
###xml 54 62 <span type="species:ncbi:9606">patients</span>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
###xml 436 444 <span type="species:ncbi:9606">patients</span>
###xml 685 693 <span type="species:ncbi:9606">patients</span>
###xml 761 769 <span type="species:ncbi:9606">patients</span>
###xml 801 805 <span type="species:ncbi:162683">Mayo</span>
###xml 1122 1126 <span type="species:ncbi:162683">Mayo</span>
###xml 1147 1154 <span type="species:ncbi:9606">Patient</span>
###xml 1278 1286 <span type="species:ncbi:9606">patients</span>
###xml 1316 1320 <span type="species:ncbi:162683">Mayo</span>
###xml 1370 1374 <span type="species:ncbi:162683">Mayo</span>
Our initial study population comprised a total of 296 patients with TDP-43 related neurodegenerative diseases, including 176 clinically diagnosed patients with ALS, FTLD and FTLD-ALS and 120 patients with pathologically confirmed TDP-43 proteinopathy. The average age at onset in the clinical cohort was 57.8+/-10.7 (range 31-81 years) and the average age at death in the pathological cohort was 74.8+/-13.8 (range 38-100 years). Among patients with known ethnicities (N = 214), 95% were Caucasian (N = 203), 3% were Hispanic (N = 7) and 2% were others (African/American (N = 2), East-Indian (N = 1) and Caribbean (N = 1)). A summary of the primary diagnoses and family history of the patients is provided in Table 1. The majority of the pathological confirmed patients (N = 87) were derived from the Mayo Clinic Jacksonville Brain Bank and primarily ascertained through The State of Florida Alzheimer's Disease Initiative funded through the Department of Elder Affairs, The Einstein Aging Study, The Udall Center for Excellence in Parkinson's Disease Research, CurePSP/The Society for Progressive Supranuclear Palsy, the Mayo Alzheimer's Disease Patient Registry (ADPR) and the Florida Alzheimer's Disease Research Center (ADRC). Additional clinical and pathological confirmed patients were ascertained through the Mayo Clinic Jacksonville and Rochester ADRC (N = 60), Mayo Clinic Scottsdale Alzheimer's Disease Center (ADC) (N = 4), the Neurological Institute of New York, Columbia University (N = 2), the University of California, Los Angeles (UCLA) ADC (N = 23), the University of British Columbia (N = 58), the Harvard Brain Bank (N = 5), the Sun Health Research Institute (N = 4), the Drexel University College of Medicine (N = 1), the Northwestern Feinberg School of Medicine (N = 13) and the Coriell Institute for Medical Research (N = 39). A list of the specific samples from the Coriell Institute included in the TARDBP mutation screening is provided as Table S3.
###end p 44
###begin p 45
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
###xml 425 429 <span type="species:ncbi:162683">Mayo</span>
To determine the frequency of the TARDBP mutations identified in our initial cohort, an additional cohort of 652 sporadic ALS patients was obtained from the University of British Columbia (N = 140), the Neurological Institute of New York, Columbia University (N = 48) and the Coriell Institute for Medical Research (N = 464). All control individuals (N = 825) included in the study were Caucasian and ascertained through the Mayo Clinics in Jacksonville, Florida and Scottsdale, Arizona.
###end p 45
###begin title 46
Sequencing Analysis
###end title 46
###begin p 47
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 155 163 151 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000193.s004">Table S4</xref>
The 5 coding and 2 non-coding exons of TARDBP were amplified by polymerase chain reaction (PCR) in standard 25 microl reactions using Qiagen PCR products (Table S4). PCR products were purified using the Agencourt Ampure method and sequenced using Big dye terminator V.3.1 products. Sequencing products were purified using the Agencourt CleanSEQ method and analyzed on an ABI 3730 DNA analyzer (Applied Biosystems, Foster City, CA, USA).
###end p 47
###begin title 48
Genotyping
###end title 48
###begin p 49
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 236 244 236 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000193.s005">Table S5</xref>
###xml 116 124 <span type="species:ncbi:9606">patients</span>
The presence of TARDBP mutations c.1009A>G (p.M337V), c.1035 C>A (p.N345K) and c.1147 A>G (p.I383V) in sporadic ALS patients and control individuals was determined with custom-designed TaqMan SNP genotyping assays (Applied Biosystems) (Table S5) and analyzed on an ABI7900 genetic analyzer using SDS2.2.2 software.
###end p 49
###begin title 50
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
TARDBP Copy-Number Analyses
###end title 50
###begin p 51
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PSEN2</italic>
###xml 183 191 183 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000193.s006">Table S6</xref>
###xml 229 235 229 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 406 412 406 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 441 447 441 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 265 273 <span type="species:ncbi:9606">patients</span>
TaqMan gene expression assays to exons 2, 4 and 6 of TARDBP and to exon 5 of PSEN2 (for use as endogenous control) were designed using File Builder 3.1 software (Applied Biosystems) (Table S6) to test for the presence of genomic TARDBP copy-number mutations in 208 patients selected from our population. This approach was used to detect copy-number mutations affecting exons 2, 4 or 6, as well as complete TARDBP and large N- and C-terminal TARDBP deletions and multiplications. Real-time PCR with 25 ng genomic DNA as template was performed on an ABI7900 using the TaqMan method according to standard procedures. All samples were run in triplicate. The FAM-fluorescent signal was analyzed using SDS2.2.2 software, and genomic copy number determined by relative quantification (DeltaDeltact method).
###end p 51
###begin title 52
p.M337V Allele Sharing Studies
###end title 52
###begin p 53
###xml 158 164 158 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 700 726 700 726 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">FAM-CAGCATCATGTGGTTTGGCAGT</named-content>
###xml 742 763 742 763 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CAGCTCGCAGGGAAGATGAAA</named-content>
###xml 779 805 779 805 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">FAM-TGGCCATCTTAACAGGAACAGC</named-content>
###xml 823 844 823 844 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TTCAAGGGCTTTCGAGGTGAA</named-content>
###xml 170 178 <span type="species:ncbi:9606">patients</span>
###xml 255 262 <span type="species:ncbi:9606">patient</span>
To examine whether the US and UK families carrying the p.M337V mutation shared a common founder, we typed 12 STR markers spanning a region of 6.7 Mb flanking TARDBP in 3 patients and 8 unaffected relatives of the previously published UK family, in the US patient ND10588 and in 2 CEPH samples. STR markers were amplified with one fluorescently labeled primer and PCR fragments were analyzed on an automated ABI3100 DNA analyzer. Alleles were scored using the Genemapper software (Applied Biosystems). CEPH allele frequencies were used to estimate the allele frequency of the shared alleles in control individuals (CEPH genotype database; ). The 2 novel markers were PCR amplified using Chr1_11.06-F: FAM-CAGCATCATGTGGTTTGGCAGT, Chr1_11.06-R: CAGCTCGCAGGGAAGATGAAA, Chr1_11.28-F: FAM-TGGCCATCTTAACAGGAACAGC and Chr1_11.28-R:TTCAAGGGCTTTCGAGGTGAA and allele frequencies were estimated in a population of 93 unrelated US control individuals.
###end p 53
###begin title 54
Cell Culture and Treatment
###end title 54
###begin p 55
H4 neuroglioma cells were grown in Opti-Mem plus 10% FBS and 1% pen-strep. Cells were plated in 6-well plates and at 90% confluency treated with 10 microM proteasome inhibitor I (PSI) (EMD Chemicals, Inc. San Diego, CA) or 100 microM pan-caspase inhibitor (Z-VAD-FMK) (EMD Chemicals, Inc. San Diego, CA) separately or in combination. Twenty-four hours after treatment, cells were harvested for subsequent Western blot analysis in the Co-IP buffer (50 mM Tris-HCl, pH 7.4, 1 M NaCl, 1% Triton-X-100, 5 mM EDTA) plus 1% SDS, PMSF, protease and phosphatase inhibitors. A similar experiment was performed using 10 microM MG-132 (Calbiochem, San Diego, CA) instead of PSI.
###end p 55
###begin title 56
Fractionation Experiment
###end title 56
###begin p 57
###xml 86 92 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 130 136 130 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Lymphoblastoid cells from 5 healthy control individuals, 3 familial ALS patients with TARDBP mutations and 2 ALS patients without TARDBP mutations were grown in RPMI1640 plus 10% FBS and 1% pen-strep. Cells were plated in T25 flasks and treated the following day with MG-132 (20 microM, 6 hours). Cell pellets from each cell line were lysed with the 0.2% Triton X-100-PBS with PMSF, protease and phosphatase inhibitors on ice for 10 minutes. After sonication, samples were centrifuged at 10,000 g for 15 minutes at 4degreesC. The supernatant was saved as the soluble fraction and the pellet was resuspended, sonicated in 2% SDS-PBS-Urea and saved as the insoluble fraction. The soluble and insoluble fractions were subjected to Western blot analysis.
###end p 57
###begin title 58
Western Blot Analysis
###end title 58
###begin p 59
###xml 389 395 <span type="species:ncbi:9986">rabbit</span>
###xml 469 475 <span type="species:ncbi:9986">rabbit</span>
###xml 589 594 <span type="species:ncbi:10090">mouse</span>
###xml 776 781 <span type="species:ncbi:10090">mouse</span>
###xml 790 796 <span type="species:ncbi:9986">rabbit</span>
###xml 815 826 <span type="species:ncbi:3704">horseradish</span>
Protein concentrations of cells lysates were measured by a standard BCA assay (Pierce, Rockford, IL). Next, samples were heated in Laemmli's buffer and equal amounts of protein were loaded into 10-well 10% or 4-20% Tris-glycine gels (Novex, San Diego, CA). After transfer, blots were blocked with 5% nonfat dry milk in TBST (TPS plus 0.1% Triton X-100) for 1 hour, and then incubated with rabbit polyclonal TDP-43 antibody (1:500; ProteinTech Group, Inc, Chicago, IL), rabbit polyclonal caspase-3 antibody (1:1000; Cell Signaling, Beverly, MA), HSP70 (1:2000; Stressgen, Ann Arbor, MI) or mouse monoclonal beta-actin antibody (1:5000, Sigma, Saint Louis, MS) overnight at 4degreesC. Membranes were washed three times each for 10 minutes with TBST and then incubated with anti-mouse or anti-rabbit IgG conjugated to horseradish peroxidase (1:2000; Jackson ImmunoResearch, West Grove, PA) for 1 hour. Membranes were then washed three times each for 10 minutes, and protein expression was visualized by ECL treatment and exposure to film.
###end p 59
###begin title 60
Supporting Information
###end title 60
###begin p 61
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
Sequence variants identified in TARDBP.
###end p 61
###begin p 62
(0.07 MB DOC)
###end p 62
###begin p 63
Click here for additional data file.
###end p 63
###begin p 64
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
Distribution of Upper and Lower Motor Neuron signs in TARDBP mutation carriers.
###end p 64
###begin p 65
(0.03 MB DOC)
###end p 65
###begin p 66
Click here for additional data file.
###end p 66
###begin p 67
###xml 60 66 60 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
Specific samples from the Coriell Institute included in the TARDBP mutation analyses.
###end p 67
###begin p 68
(0.07 MB DOC)
###end p 68
###begin p 69
Click here for additional data file.
###end p 69
###begin p 70
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
TARDBP PCR and sequencing primers.
###end p 70
###begin p 71
(0.03 MB DOC)
###end p 71
###begin p 72
Click here for additional data file.
###end p 72
###begin p 73
###xml 23 29 23 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
Primers and probes for TARDBP copy-number analyses.
###end p 73
###begin p 74
(0.03 MB DOC)
###end p 74
###begin p 75
Click here for additional data file.
###end p 75
###begin p 76
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
Detailed Information on TARDBP Taqman genotyping assays.
###end p 76
###begin p 77
(0.03 MB DOC)
###end p 77
###begin p 78
Click here for additional data file.
###end p 78
###begin p 79
###xml 192 197 <span type="species:ncbi:9606">Human</span>
We would like to thank the families who contributed samples that were critically important for this study. ALS samples from the National Institute of Neurological Disorders and Stroke (NINDS) Human Genetics Resource Center DNA and Cell Line Repository () and the ALS Research Group (ALSRG) were included in this study.
###end p 79
###begin title 80
References
###end title 80
###begin article-title 81
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
###end article-title 81
###begin article-title 82
Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43.
###end article-title 82
###begin article-title 83
TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis.
###end article-title 83
###begin article-title 84
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
###end article-title 84
###begin article-title 85
Etiology and pathophysiology of frontotemporal dementia, Parkinson disease and Alzheimer disease: lessons from genetic studies.
###end article-title 85
###begin article-title 86
Disturbance of nuclear and cytoplasmic Tar DNA binding protein (TDP-43) induces disease-like redistribution, sequestration and aggregate formation.
###end article-title 86
###begin article-title 87
Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43.
###end article-title 87
###begin article-title 88
TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease.
###end article-title 88
###begin article-title 89
TAR-DNA binding protein 43 in Pick disease.
###end article-title 89
###begin article-title 90
Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies.
###end article-title 90
###begin article-title 91
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases.
###end article-title 91
###begin article-title 92
Hippocampal sclerosis dementia: a reappraisal.
###end article-title 92
###begin article-title 93
###xml 70 75 <span type="species:ncbi:9606">human</span>
Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease.
###end article-title 93
###begin article-title 94
Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping.
###end article-title 94
###begin article-title 95
###xml 89 94 <span type="species:ncbi:9606">human</span>
Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene.
###end article-title 95
###begin article-title 96
The Microprocessor complex mediates the genesis of microRNAs.
###end article-title 96
###begin article-title 97
Incidence of ALS in Italy: evidence for a uniform frequency in Western countries.
###end article-title 97
###begin article-title 98
Complex genetics of amyotrophic lateral sclerosis.
###end article-title 98
###begin article-title 99
The genetics of frontotemporal lobar degeneration.
###end article-title 99
###begin article-title 100
Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.
###end article-title 100
###begin article-title 101
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.
###end article-title 101
###begin article-title 102
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17.
###end article-title 102
###begin article-title 103
Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21.
###end article-title 103
###begin article-title 104
Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration.
###end article-title 104
###begin article-title 105
A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia.
###end article-title 105
###begin article-title 106
Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia.
###end article-title 106
###begin article-title 107
Three families with amyotrophic lateral sclerosis and frontotemporal dementia with evidence of linkage to chromosome 9p.
###end article-title 107
###begin article-title 108
Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3.
###end article-title 108
###begin article-title 109
Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein.
###end article-title 109
###begin article-title 110
TDP-43 A315T mutation in familial motor neuron disease.
###end article-title 110
###begin article-title 111
TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis.
###end article-title 111
###begin article-title 112
TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis.
###end article-title 112
###begin article-title 113
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease.
###end article-title 113
###begin article-title 114
Missense and splice site mutations in tau associated with FTDP-17: multiple pathogenic mechanisms.
###end article-title 114
###begin article-title 115
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis.
###end article-title 115
###begin article-title 116
Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS.
###end article-title 116
###begin article-title 117
TDP-43 gene analysis in frontotemporal lobar degeneration.
###end article-title 117
###begin article-title 118
No association of TDP-43 with sporadic frontotemporal dementia.
###end article-title 118
###begin article-title 119
Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder: evidence for a linked protective factor.
###end article-title 119
###begin article-title 120
D90A-SOD1 mediated amyotrophic lateral sclerosis: a single founder for all cases with evidence for a Cis-acting disease modifier in the recessive haplotype.
###end article-title 120
###begin p 121
The authors have declared that no competing interests exist.
###end p 121
###begin p 122
###xml 40 44 <span type="species:ncbi:162683">Mayo</span>
###xml 72 76 <span type="species:ncbi:162683">Mayo</span>
###xml 803 807 <span type="species:ncbi:162683">Mayo</span>
This work was supported by NIH funding: Mayo Clinic ADRC (P50 AG16574), Mayo Clinic ADPR (U01 AG06786), R01 NS42759, R01 NS42759-04S1, P30 AG13854, AG19610-01, P50 AG25711, P01 AG17216, P50 NS 40256, P01 AG03949, R01 AG15866, R01 AG026251-01 and the Morris K. Udall NIH/NINDS PD Center of Excellence award (NS40256). In addition, the authors received support from the Pacific Alzheimer's Research Foundation (PARF) # C06-01, Canadian Institutes of Health Research grant #74580, The Potamkin Foundation, The Justice Newmann Fund, The Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program, The M. L. Simpson Foundation Trust, Canada Research Chairs, PrioNet Canada, Amorfix Life Sciences, Cure PSP/Society for PSP, The State of Florida Department of Elder Affairs and the Mayo Foundation. Sponsors and funders had no role in study design, data collection, analysis or interpretation, or manuscript preparation, review or approval.
###end p 122

